Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines that have been scored and published by ESMO.

It includes all cancer medicines approved by the European Medicines Agency (from January 2016) and the US Food and Drug Administration (from January 2020).

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 20
4 105
3 140
2 36
1 21
Curative setting
A 41
C 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 2
Breast Cancer 34
Central Nervous System Malignancies 1
Endocrine Tumours 20
Gastrointestinal Cancers 59
Genitourinary Cancers 54
Gynaecological Malignancies 32
Head and neck cancer 9
Melanoma 21
RET fusion-positive tumours 1
Refractory NTRK fusion–positive cancers 2
Sarcoma 9
Skin Cancers 6
TMB-H solid tumours 1
Thoracic Malignancies 70
dMMR/MSI-H solid tumours 1
Curative setting
Brain Tumours 0
Breast Cancer 7
Central Nervous System Malignancies 1
Endocrine Tumours 0
Gastrointestinal Cancers 15
Genitourinary Cancers 3
Gynaecological Malignancies 0
Head and neck cancer 0
Melanoma 11
RET fusion-positive tumours 0
Refractory NTRK fusion–positive cancers 0
Sarcoma 2
Skin Cancers 1
TMB-H solid tumours 0
Thoracic Malignancies 4
dMMR/MSI-H solid tumours 0

The ESMO-MCBS Scorecards

The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in “orphan diseases” and for diseases with “high unmet need” when primary outcome is PFS or ORR.
Quality of Life Checklist To evaluate ESMO-MCBS score adjustments based on quality of life

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Treatment Setting Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Tremelimumab Durvalumab Sorafenib EMA: Treatment for adult patients in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma - FDA: Treatment for adult patients in combination with durvalumab with unresectable hepatocellular carcinoma Gastrointestinal Cancers Hepatobiliary Cancers - Hepatocellular Carcinoma - HIMALAYA
    5

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      1
    Pembrolizumab - Single arm (Phase II) For patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. Skin Cancers Cutaneous Squamous Cell Carcinoma - KEYNOTE-629
    3

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Cemiplimab - Single arm (Phase II) For the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation Skin Cancers Cutaneous Squamous Cell Carcinoma - R2810-ONC-1423/R2810-ONC-1540
    4

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Cemiplimab - Investigator's choice of ChT Indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy Gynaecological Malignancies Cervical Cancer - EMPOWER-Cervical 1
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Tremelimumab Durvalumab and platinum-based ChT Platinum-based ChT EMA: First-line treatment of tremelimumab in combination with durvalumab and platinum-based chemotherapy (ChT) for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations - FDA: Tremelimumab in combination with durvalumab and platinum-based ChT for adult patients with metastatic NSCLC with no EGFR mutation or ALK genomic tumor aberrations. Thoracic Malignancies Non-small-cell Lung Cancer - POSEIDON
    4

    PRELIMINARY SCORE

    • OS
      5

    ADJUSTMENTS

    FINAL SCORE

    • F1
      2
    Abemaciclib - Single arm (Phase II) Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following ET and prior ChT in the metastatic setting Breast Cancer Breast Cancer HR+, HER2- MONARCH 1
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Bevacizumab Capecitabine Placebo + capecitabine First-line treatment of patients with metastatic breast cancer in whom treatment with other ChT options, including taxanes or anthracyclines, is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with bevacizumab–capecitabine Breast Cancer Breast Cancer - RIBBON-1
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Olaparib Abiraterone and prednisone or prednisolone Placebo + abiraterone and prednisone or prednisolone In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer in whom chemotherapy is not clinically indicated  Genitourinary Cancers Prostate cancer - PROpel
    2

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      4
    Relatlimab Nivolumab Nivolumab First line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression <1%. Melanoma Cutaneous Melanoma PD-L1 expression <1% RELATIVITY-047
    3

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      3
    Adagrasib - Single arm (Phase I/II) For adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy Thoracic Malignancies Non-small-cell Lung Cancer KRAS G12C KRYSTAL-1
    2

    PRELIMINARY SCORE

    • OS
      6

    ADJUSTMENTS

    FINAL SCORE

    • F1
      4

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.